TransMedics Group (TMDX) Tops Q4 EPS by $2.23, provides guidance

TransMedics Group (NASDAQ: TMDX) reported Q4 EPS of $2.62, $2.23 better than the analyst estimate of $0.39. Revenue for the quarter came in at $160.8 million versus the consensus estimate of $155.98 million.

GUIDANCE:

TransMedics Group sees FY2026 revenue of $727-757 million, versus the consensus of $725 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• Jefferies on QuidelOrtho (QDEL): 'we view a potential sale as a net positive'
• Gorilla Technology raises Q2 2026 revenue outlook to $44M
• Redwire Corporation (RDW) call put ratio 4.2 calls to 1 put with a focus on July 2 weekly calls